#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Macular telangiectasia High-grade B-cell lymphoma Endometrial cancer recurrent Antiphospholipid antibodies Spinal cord injury cervical Eosinophilic granulomatosis with polyangiitis Mucopolysaccharidosis I Neuroendocrine carcinoma metastatic Salivary gland cancer Malformation venous Hereditary ataxia Granulomatosis with polyangiitis Cerebral amyloid angiopathy Craniocerebral injury Squamous cell carcinoma of head and neck More trials…

    Learn about Rare Diseases

    Breast angiosarcoma metastatic Propionic acidaemia – Basic Information Methylmalonic acidaemia – Diagnostics Erdheim-Chester disease – Treatment Turner’s syndrome – Diagnostics Hereditary hypophosphataemic rickets Loeys-Dietz syndrome Adrenocortical carcinoma Von Willebrand’s disease – Treatment Glycogen storage disease type V – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Clindamycin Hydrochloride Hyoscine Butylbromide Valproate Semisodium Ferric Derisomaltose Aficamten FERUMOXTRAN-10 Clonidine Hydrochloride Defactinib Satoreotide Tetraxetan Fluasterone Ergocalciferol Fingolimod Chlorpromazine Hydrochloride Lovastatin SAR445399 Allo-647 Leflunomide Midazolam Anselamimab Glyceryl Trinitrate More therapies…

    Learn about Your Condition

    Breast conserving surgery Pelvic venous thrombosis Conjunctivitis allergic Von Hippel-Lindau disease Biliary adenoma Genital herpes simplex Pulmonary fibrosis Crigler-Najjar syndrome Brain neoplasm malignant Sarcoidosis Endometrial cancer stage I Mitral valve incompetence Proteus syndrome Ocular hypertension Anogenital warts More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik

Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik

ul. Wiejska 81, Bialystok, 15-351, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Deucravacitinib
    Czechia Finland France Germany Hungary Poland +2

  • Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Previously Used Anti-TNF Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Tildrakizumab
    Czechia Estonia Germany Italy Poland Slovakia +1

  • Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Not Used Anti-TNF Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Tildrakizumab
    Czechia Germany Poland Spain

  • Study on the Effectiveness and Safety of JNJ-77242113 for Treating Moderate to Severe Plaque Psoriasis in Adults

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Jnj-77242113
    France Germany Hungary Italy Poland Spain

  • Study on Deucravacitinib for Patients with Active Psoriatic Arthritis New to Biologic Treatments

    Not recruiting

    3 1
    Investigated Drugs:
    • Deucravacitinib
    Bulgaria Czechia Finland France Hungary Ireland +4

  • Study on Upadacitinib for Adults with Active Axial Spondyloarthritis

    Not recruiting

    3 1
    Investigated Diseases:
    • Ankylosing spondylitis
    • Axial spondyloarthritis
    Investigated Drugs:
    • Abt-494
    Belgium Bulgaria Czechia France Germany Hungary +3

  • Study Comparing Upadacitinib, Placebo, and Adalimumab for Patients with Moderate to Severe Rheumatoid Arthritis on Stable Methotrexate Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Adalimumab
    • Upadacitinib
    Belgium Bulgaria Croatia Czechia Estonia France +11

  • Study on Long-Term Safety and Efficacy of Tildrakizumab for Adults with Psoriatic Arthritis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Tildrakizumab
    Czechia Estonia Germany Italy Poland Slovakia +1

  • Study on Izokibep for Improving Symptoms in Patients with Active Psoriatic Arthritis

    Not recruiting

    4 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Izokibep
    Bulgaria Czechia Germany Hungary Poland Spain

  • Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Axial spondyloarthritis
    Investigated Drugs:
    • Filgotinib
    Belgium Bulgaria Croatia Czechia Estonia France +9
Previous Page
1 2 3 4 5
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!